Risperidone versus placebo for people with schizophrenia

14397363653_f60cbb91b2_k

Joanne Wallace summarises the recent Cochrane systematic review on risperidone versus placebo for schizophrenia, which concludes that the best available evidence does not show that the benefits of risperidone outweigh the harms.

[read the full story...]

Antipsychotic efficacy measured by real-world observational study

telescope-1082091_640

Tracey Roberts examines whether a retrospective observational study accurately investigates the effectiveness of second and first generation antipsychotics.

[read the full story...]

ITI-007 for schizophrenia

9243814710_c193bba8da_k

Murtada Alsaif summarises a recent 4-week long phase II randomised controlled trial of ITI-007 for the treatment of schizophrenia, which contains some positive results for this novel intervention.

[read the full story...]

Biological pathways, antipsychotics and schizophrenia

1622916980_ba3ea68e3e_b

Murtada Alsaif summarises a small cohort study that uses shotgun mass spectrometry proteomic profiling to unravel the molecular pathways involved with antipsychotic response in people with schizophrenia.

[read the full story...]

The antipsychotic drugs don’t work for anorexia nervosa

Refusing pills

Helen Bould appraises a recent meta-analysis of second-generation antipsychotics for anorexia nervosa, which finds that the drugs don’t lead to weight gain or improve eating disorder symptoms. So why are antipsychotics being used in this group of patients?

[read the full story...]

The more psychotic you are, the more benefit there is in taking antipsychotics

shutterstock_122223547

John Baker reviews a recent participant-level meta-analysis of six placebo-controlled studies, which looks at the initial severity of schizophrenia and the efficacy of antipsychotics including Olanzapine, Risperidone and Amisulpride.

[read the full story...]

Long-acting antipsychotics cost-effective for treatment of schizophrenia, but evidence inconsistent

shutterstock_95098696

Here at Mental Elf HQ we’re expanding our skill set to include economics. Understanding the best way to value health and health care, and improving health outcomes with budget constraints in mind, are the key pastimes of economics elves. We hope to bring you the latest economic evidence in the field of mental health and to [read the full story…]

What was the respective effectiveness of olanzapine vs. risperidone in treating aggressive behaviours in adults with learning disability?

Argument

  New generation anti-psychotic medications are being used to treat aggressive behaviours in people with learning disabilities, whether or not individuals have a formal diagnosis of a mental health problem. This study set out to evaluate the effectiveness of two such new generation anti-psychotic medications, olanzapine and risperidone. The study looked at how effective these [read the full story…]